Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 244,787,200
  • Shares Outstanding, K 6,830,000
  • Annual Sales, $ 67,325 M
  • Annual Income, $ 12,808 M
  • EBIT $ 0 M
  • EBITDA $ 21,007 M
  • 60-Month Beta 0.44
  • Price/Sales N/A
  • Price/Cash Flow 11.63
  • Price/Book 7.31
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/01/24
  • Annual Dividend & Yield 0.85 (2.36%)
  • Most Recent Dividend 0.847 on 03/14/24
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.5000 +0.25%
on 11/18/24
40.6700 -12.49%
on 10/25/24
-3.9700 (-10.04%)
since 10/18/24
3-Month
35.5000 +0.25%
on 11/18/24
42.4300 -16.12%
on 08/30/24
-4.9700 (-12.25%)
since 08/16/24
52-Week
29.2000 +21.88%
on 05/02/24
42.4300 -16.12%
on 08/30/24
+2.2000 (+6.59%)
since 11/17/23

Most Recent Stories

More News
Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory News

This week, Roche RHHBY announced its third-quarter and nine-month results. Sanofi SNY confirmed that it is holding exclusive talks with U.S. private equity company CD&R to sell a controlling stake in its...

AZN : 63.17 (-0.09%)
NVO : 100.12 (-1.59%)
RHHBY : 35.5900 (-0.70%)
PFE : 24.86 (+0.24%)
SNY : 48.12 (+0.31%)
Should AbbVie Stock Be in Your Portfolio Pre-Q3 Earnings?

AbbVie ABBV is set to report third-quarter earnings on Oct. 30, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $14.28 billion and $2.93 per share, respectively.The...

NVO : 100.12 (-1.59%)
JNJ : 153.80 (-0.13%)
LLY : 718.18 (-3.76%)
ABBV : 166.09 (+0.67%)
RHHBY : 35.5900 (-0.70%)
CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases

Shares of Catalent CTLT lost 0.9% on Oct. 23 with the rise in uncertainty related to its acquisition by Novo Holding following a report from Reuters on opposition from several large pharma companies as...

NVO : 100.12 (-1.59%)
CTLT : 58.64 (-0.78%)
LLY : 718.18 (-3.76%)
RHHBY : 35.5900 (-0.70%)
Health and Wellness Industry Embraces Surge in Demand for Weight Loss Drugs

/CNW/ -- USA News Group News Commentary – With more than 100 million Americans struggling with obesity, and obesity rates increasing on every continent, it's...

VKTX : 49.60 (+0.04%)
NVO : 100.12 (-1.59%)
MS : 134.93 (+0.65%)
LLY : 718.18 (-3.76%)
RHHBY : 35.5900 (-0.70%)
VEGA.CN : 0.3550 (-5.33%)
PLTXF : 0.2460 (-1.01%)
Vabysmo, Hemlibra Drive Roches Sales in Q3 & First 9 Months of 2024

Swiss pharma giant Roche Holding AG RHHBY posted strong growth in the third quarter. Sales increased 6% year over year to CHF 15.1 billion and were up 9% at constant exchange rates (CER).Stay up-to-date...

NVO : 100.12 (-1.59%)
LLY : 718.18 (-3.76%)
REGN : 755.27 (-0.20%)
RHHBY : 35.5900 (-0.70%)
Can Roche Challenge Lilly and Novo in the Weight Loss Market?

One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.

NVO : 100.12 (-1.59%)
LLY : 718.18 (-3.76%)
GPCR : 30.91 (-9.54%)
RHHBY : 35.5900 (-0.70%)
The Zacks Analyst Blog Highlights Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi

For Immediate ReleaseChicago, IL – October 22, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

JNJ : 153.80 (-0.13%)
ABBV : 166.09 (+0.67%)
RHHBY : 35.5900 (-0.70%)
PFE : 24.86 (+0.24%)
SNY : 48.12 (+0.31%)
Pharma Stock Roundup: JNJ's Q3 Earnings, FDA Nod to Some New Drugs

This week, Johnson & Johnson JNJ began the third-quarter earnings season for the drug and biotech sector. The FDA granted approval to a few new drugs, which included Pfizer’s PFE gene therapy for hemophilia,...

JNJ : 153.80 (-0.13%)
ABBV : 166.09 (+0.67%)
RHHBY : 35.5900 (-0.70%)
PFE : 24.86 (+0.24%)
SNY : 48.12 (+0.31%)
Biotech Advances Gain Momentum Amid October’s Rising Breast Cancer Rates and Awareness Efforts

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Each October, breast cancer awareness gains momentum through impactful campaigns and advancements in...

ONCY : 0.9900 (+1.02%)
PCSA : 1.0300 (+1.99%)
JAGX : 0.9797 (+2.05%)
BCTX : 0.5990 (+0.67%)
ONC.TO : 1.40 (+1.45%)
RHHBY : 35.5900 (-0.70%)
Roche Wins FDA Nod for Breast Cancer Drug in First-Line Setting

Roche RHHBY announced that the FDA has approved pipeline candidate, inavolisib, for the treatment of breast cancer, under the brand name Itovebi.The drug is approved in combination with Pfizer’s Ibrance...

BAYRY : 5.3100 (-0.93%)
NVS : 102.93 (-0.13%)
RHHBY : 35.5900 (-0.70%)
SNY : 48.12 (+0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its...

See More

Key Turning Points

3rd Resistance Point 36.3400
2nd Resistance Point 36.2000
1st Resistance Point 36.0200
Last Price 35.5900
1st Support Level 35.7000
2nd Support Level 35.5600
3rd Support Level 35.3800

See More

52-Week High 42.4300
Fibonacci 61.8% 37.3761
Fibonacci 50% 35.8150
Last Price 35.5900
Fibonacci 38.2% 34.2539
52-Week Low 29.2000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar